



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter David ~~David~~, Matthew Alexander Naylor, Peter Thomson,
Steven Albert Everett, Michael Richard Lacey Stratford and Peter Wardman

Application No.: 10/550,982 Group: 1626

Filed (371(c) Date): October 27, 2005 Examiner: Barker, Michael P.

Confirmation No.: 1643

For: Bioreductively Activated Stilbene Prodrugs

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
May 10, 2007	<i>Rachel Wright</i>
Date	Signature
Rachel Wright	
Typed or printed name of person signing certificate	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
☐ a Statement under 37 CFR 1.97(e), as checked below, or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(e), as checked below, and
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application file.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references are enclosed.
 - ☒ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.
 - ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
 - ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:
(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.


Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By



Alice O. Carroll


Registration No. 33,542

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:



PTO-1449 REPRODUCED

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

May 10, 2007

(use several sheets if necessary)

ATTORNEY DOCKET NO.
3963.1000-000

APPLICATION NO.
10/550,982

FIRST NAMED INVENTOR
Peter David Davis

371(c) FILING DATE
October 27, 2005

EXAMINER
Barker, Michael P.

CONFIRMATION NO.
1643


GROUP
1626

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A2	4,996,237	02-26-1991	Pettit <i>et al.</i>
	A3	5,569,786	10-29-1996	Pettit <i>et al.</i>
	A4	5,633,158	05-27-1997	Anlezark <i>et al.</i>
	A5	5,731,353	03-24-1998	Ohsumi <i>et al.</i>
	A6	5,977,065	11-02-1999	Anlezark <i>et al.</i>
	A7			
	A8			
	A9			
	A10			
	A11			
	A12			
	A13			
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3963.1000-000		APPLICATION NO. 10/550,982	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION  May 10, 2007 (Use several sheets if necessary)		FIRST NAMED INVENTOR Peter David Davis		371(c) FILING DATE October 27, 2005	
		EXAMINER Barker, Michael P.		CONFIRMATION NO. 1643	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	B5	WO 00/47725 A1	08-17-2000	Microbiological Research Authority		
	B6	WO 00/64864 A1	11-02-2000	Cancer Research Campaign Technology Limited		
	B5					
	B6					
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					
	B15					
	B16					
	B17					
	B18					
	B19					
	B20					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATION**

May 10, 2007

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3963.1000-000

APPLICATION NO.
10/550,982


FIRST NAMED INVENTOR
Peter David Davis

371(c) FILING DATE
October 27, 2005

EXAMINER
Barker, Michael P.

CONFIRMATION NO.
1643

GROUP
1626



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C4	Kennedy, Katherine A., <i>et al.</i> , "Preferential Activation of Mitomycin C to Cytotoxic Metabolites by Hypoxic Tumor Cells", <i>Cancer Research</i> , 40:2356-2360 (1980).
C5	Denny, William A., "The Role of Hypoxia-Activated Prodrugs in Cancer Therapy", <i>The Lancet Oncology</i> , 1:25-29 (2000).
C6	Rothschild, Bruce M., <i>et al.</i> , "Pathogenesis of Rheumatoid Arthritis: A Vascular Hypothesis", <i>Seminars in Arthritis and Rheumatism</i> , 12(1):11-31 (1982).
C7	Dvorak, Harold F., "Vascular Permeability Factor/Vascular Endothelial Growth Factor: An Important Mediator of Angiogenesis in Malignancy and Inflammation", <i>Int. Arch. Allergy Immunol.</i> , 107:233-235 (1995).
C8	Das, Arup, <i>et al.</i> , "Retinal and Choroidal Angiogenesis: Pathophysiology and Strategies for Inhibition", <i>Progress in Retinal and Eye Research</i> , 22:721-748 (2003).
C9	Naylor, M. A., <i>et al.</i> , "Recent Advances in Bioreductive Drug Targeting", <i>Mini Reviews in Medicinal Chemistry</i> , 1:17-29 (2001).
C10	Tercel, Moana, <i>et al.</i> , "Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine", <i>J. Med. Chem.</i> , 44:3511-3522 (2001).
C11	Damen, Eric W.P., <i>et al.</i> , "Synthesis of Novel Paclitaxel Prodrugs Designed for Bioreductive Activation in Hypoxic Tumour Tissue", <i>Bioorganic & Medicinal Chemistry</i> , 10:71-77 (2002).
C12	Papot, S., <i>et al.</i> , "Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies", <i>Curr. Med. Chem. - Anti-Cancer Agents</i> , 2:155-185 (2002).
C13	Skelly, Jane V., <i>et al.</i> , "Aerobic Nitroreduction by Flavoproteins: Enzyme Structure, Mechanisms, and Role in Cancer Chemotherapy", <i>Mini Reviews in Medicinal Chemistry</i> , 1:293-306 (2001).
C14	Woods, J.A., <i>et al.</i> , "The Interaction with Tubulin of a Series of Stilbenes Based on Combretastatin A-4", <i>British Journal of Cancer</i> , 71:705-711 (1995).
C15	
C16	

EXAMINER

DATE CONSIDERED